|
1
|
Cascieri MA and Bayne ML: Analysis of the
interaction of IGF-I analogs with the IGF-I receptor and IGF
binding proteins. Adv Exp Med Biol. 343:33–40. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hayashi Y, Asuzu DT, Gibbons SJ, Aarsvold
KH, Bardsley MR, Lomberk GA, Mathison AJ, Kendrick ML, Shen KR,
Taguchi T, et al: Membrane-to-nucleus signaling links insulin-like
growth factor-1- and stem cell factor-activated pathways. PLoS One.
8:e768222013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amutha P and Rajkumar T: Role of
insulin-like growth factor, insulin-like growth factor receptors,
and insulin-like growth factor-binding proteins in ovarian cancer.
Indian J Med Paediatr Oncol. 38:198–206. 2017.PubMed/NCBI
|
|
5
|
Wan X, Harkavy B, Shen N, Grohar P and
Helman LJ: Rapamycin induces feedback activation of akt signaling
through an igf-1R-dependent mechanism. Oncogene. 26:1932–1940.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen HX and Sharon E: IGF-1R as an
anti-cancer target-trials and tribulations. Chin J Cancer.
32:242–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi WJ and Gao JB: Molecular mechanisms of
chemoresistance in gastric cancer. World J Gastrointest Oncol.
8:673–681. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu JP, Baker J, Perkins AS, Robertson EJ
and Efstratiadis A: Mice carrying null mutations of the genes
encoding insulin-like growth factor I (Igf-1) and type 1 IGF
receptor (Igf1r). Cell. 75:59–72. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ward CW and Garrett TP: Structural
relationships between the insulin receptor and epidermal growth
factor receptor families and other proteins. Curr Opin Drug Discov
Devel. 7:630–638. 2004.PubMed/NCBI
|
|
10
|
Siddle K: The insulin receptor and type I
IGF receptor: Comparison of structure and function. Prog Growth
Factor Res. 4:301–320. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wit JM and Walenkamp MJ: Role of
insulin-like growth factors in growth, development and feeding.
World Rev Nutr Diet. 106:60–65. 2013.PubMed/NCBI
|
|
12
|
Yakar S, Kim H, Zhao H, Toyoshima Y,
Pennisi P, Gavrilova O and Leroith D: The growth hormone-insulin
like growth factor axis revisited: Lessons from IGF-1 and IGF-1
receptor gene targeting. Pediatr Nephrol. 20:251–254. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Russo VC, Gluckman PD, Feldman EL and
Werther GA: The insulin-like growth factor system and its
pleiotropic functions in brain. Endocr Rev. 26:916–943. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laustsen PG, Russell SJ, Cui L,
Entingh-Pearsall A, Holzenberger M, Liao R and Kahn CR: Essential
role of insulin and insulin-like growth factor 1 receptor signaling
in cardiac development and function. Mol Cell Biol. 27:1649–1664.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moody G, Beltran PJ, Mitchell P, Cajulis
E, Chung YA, Hwang D, Kendall R, Radinsky R, Cohen P and Calzone
FJ: IGF1R blockade with ganitumab results in systemic effects on
the GH-IGF axis in mice. J Endocrinol. 221:145–155. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Delafontaine P, Song YH and Li Y:
Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1
binding proteins in blood vessels. Arterioscler Thromb Vasc Biol.
24:435–444. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao S, Wassler M, Zhang L, Li Y, Wang J,
Zhang Y, Shelat H, Williams J and Geng YJ: MicroRNA-133a regulates
insulin-like growth factor-1 receptor expression and vascular
smooth muscle cell proliferation in murine atherosclerosis.
Atherosclerosis. 232:171–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Werner H: Tumor suppressors govern
insulin-like growth factor signaling pathways: Implications in
metabolism and cancer. Oncogene. 31:2703–2714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schayek H, Bentov I, Sun S, Plymate SR and
Werner H: Progression to metastatic stage in a cellular model of
prostate cancer is associated with methylation of the androgen
receptor gene and transcriptional suppression of the insulin-like
growth factor-I receptor gene. Exp Cell Res. 316:1479–1488. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
O'Connor R, Kauffmann-Zeh A, Liu Y, Lehar
S, Evan GI, Baserga R and Blättler WA: Identification of domains of
the insulin-like growth factor I receptor that are required for
protection from apoptosis. Mol Cell Biol. 17:427–435. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Resnicoff M, Abraham D, Yutanawiboonchai
W, Rotman HL, Kajstura J, Rubin R, Zoltick P and Baserga R: The
insulin-like growth factor I receptor protects tumor cells from
apoptosis in vivo. Cancer Res. 55:2463–2469. 1995.PubMed/NCBI
|
|
22
|
Valentinis B and Baserga R: The IGF-I
receptor protects tumor cells from apoptosis induced by high
concentrations of serum. Biochem Biophys Res Commun. 224:362–368.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baserga R: The IGF-I receptor in cancer
research. Exp Cell Res. 253:1–6. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Samani AA, Yakar S, LeRoith D and Brodt P:
The role of the IGF system in cancer growth and metastasis:
Overview and recent insights. Endocr Rev. 28:20–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
|
26
|
Ter Braak B, Siezen CL, Lee JS, Rao P,
Voorhoeve C, Ruppin E, van der Laan JW and van de Water B:
Insulin-like growth factor 1 receptor activation promotes mammary
gland tumor development by increasing glycolysis and promoting
biomass production. Breast Cancer Res. 19:142017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peretz S, Kim C, Rockwell S, Baserga R and
Glazer PM: IGF1 receptor expression protects against
microenvironmental stress found in the solid tumor. Radiat Res.
158:174–180. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Werner H, Sarfstein R, LeRoith D and
Bruchim I: Insulin-like growth factor 1 signaling axis meets p53
genome protection pathways. Front Oncol. 6:1592016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mamula PW and Goldfine ID: Cloning and
characterization of the human insulin-like growth factor-I receptor
gene 5′-flanking region. DNA Cell Biol. 11:43–50. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Werner H, Bach MA, Stannard B, Roberts CT
Jr and LeRoith D: Structural and functional analysis of the
insulin-like growth factor I receptor gene promoter. Mol
Endocrinol. 6:1545–1558. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singh RK, Gaikwad SM, Jinager A, Chaudhury
S, Maheshwari A and Ray P: IGF-1R inhibition potentiates cytotoxic
effects of chemotherapeutic agents in early stages of
chemoresistant ovarian cancer cells. Cancer Lett. 354:254–262.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schayek H, Bentov I, Rotem I,
Pasmanik-Chor M, Ginsberg D, Plymate SR and Werner H: Transcription
factor E2F1 is a potent transactivator of the insulin-like growth
factor-I receptor (IGF-IR) gene. Growth Horm IGF Res. 20:68–72.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huo X, Liu S, Shao T, Hua H, Kong Q, Wang
J, Luo T and Jiang Y: GSK3 protein positively regulates type I
insulin-like growth factor receptor through forkhead transcription
factors FOXO1/3/4. J Biol Chem. 289:24759–72470. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Finkeltov I, Kuhn S, Glaser T, Idelman G,
Wright JJ, Roberts CT Jr and Werner H: Transcriptional regulation
of IGF-I receptor gene expression by novel isoforms of the EWS-WT1
fusion protein. Oncogene. 21:1890–1898. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Werner H and Sarfstein R: Transcriptional
and epigenetic control of IGF1R gene expression: Implications in
metabolism and cance. Growth Horm IGF Res. 24:112–118. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Idelman G, Glaser T, Roberts CT Jr and
Werner H: WT1-p53 interactions in insulin-like growth factor-I
receptor gene regulation. J Biol Chem. 278:3474–3482. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim SO, Park JG and Lee YI: Increased
expression of the insulin-like growth factor I (IGF-I) receptor
gene in hepatocellular carcinoma cell lines: Implications of IGF-I
receptor gene activation by hepatitis B virus X gene product.
Cancer Res. 56:3831–3836. 1996.PubMed/NCBI
|
|
38
|
Taliaferro-Smith L, Oberlick E, Liu T,
McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E,
Nagaraju GP, et al: FAK activation is required for IGF1R-mediated
regulation of EMT, migration, and invasion in mesenchymal triple
negative breast cancer cells. Oncotarget. 6:4757–4772. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dearth RK, Cui X, Kim HJ, Hadsell DL and
Lee AV: Oncogenic transformation by the signaling adaptor proteins
insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle.
6:705–713. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Koval AP, Blakesley VA, Roberts CT Jr,
Zick Y and Leroith D: Interaction in vitro of the product of the
c-Crk-II proto-oncogene with the insulin-like growth factor I
receptor. Biochem J. 330:923–932. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kulik G and Weber MJ: Akt-dependent and
-independent survival signaling pathways utilized by insulin-like
growth factor I. Mol Cell Biol. 18:6711–6718. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Peruzzi F, Prisco M, Dews M, Salomoni P,
Grassilli E, Romano G, Calabretta B and Baserga R: Multiple
signaling pathways of the insulin-like growth factor 1 receptor in
protection from apoptosis. Mol Cell Biol. 19:7203–7215. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brazil DP, Yang ZZ and Hemmings BA:
Advances in protein kinase B signalling: AKTion on multiple fronts.
Trends Biochem Sci. 29:233–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pollak M: Insulin, insulin-like growth
factors and neoplasia. Best Pract Res Clin Endocrinol Metab.
22:625–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Greer EL and Brunet A: FOXO transcription
factors at the interface between longevity and tumor suppression.
Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Playford MP, Bicknell D, Bodmer WF and
Macaulay VM: Insulin-like growth factor 1 regulates the location,
stability, and transcriptional activity of beta-catenin. Proc Natl
Acad Sci USA. 97:pp. 12103–12108. 2000; View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu C, Zhang Z, Tang H, Jiang Z, You L and
Liao Y: Crosstalk between IGF-1R and other tumor promoting
pathways. Curr Pharm Des. 20:2912–2921. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rota LM, Albanito L, Shin ME, Goyeneche
CL, Shushanov S, Gallagher EJ, LeRoith D, Lazzarino DA and Wood TL:
IGF1R inhibition in mammary epithelia promotes canonical Wnt
signaling and Wnt1-driven tumors. Cancer Res. 74:5668–5679. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang QY, Wang L, Song ZY and Qu XJ:
Knockdown of type I insulin-like growth factor receptor inhibits
human colorectal cancer cell growth and downstream PI3K/Akt,
WNT/β-catenin signal pathways. Biomed Pharmacother. 73:12–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Alsina-Sanchis E, Figueras A, Lahiguera Á,
Vidal A, Casanovas O, Graupera M, Villanueva A and Vinals F: The
TGFβ pathway stimulates ovarian cancer cell proliferation by
increasing IGF1R levels. Int J Cancer. 139:1894–4903. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tognon CE and Sorensen PH: Targeting the
insulin-like growth factor 1 receptor (IGF1R) signaling pathway for
cancer therapy. Expert Opin Ther Targets. 16:33–48. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Firth SM and Baxter RC: Cellular actions
of the insulin-like growth factor binding proteins. Endocr Rev.
23:824–854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Triplett TA, Cardenas KT, Lancaster JN, Hu
Z, Selden HJ, Jasso GJ, Balasubramanyam S, Chan K, Li L, Chen X, et
al: Endogenous dendritic cells from the tumor microenvironment
support T-ALL growth via IGF1R activation. Proc Natl Acad Sci USA.
113:pp. E1016–E1025. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Medyouf H, Gusscott S, Wang H, Tseng JC,
Wai C, Nemirovsky O, Trumpp A, Pflumio F, Carboni J, Gottardis M,
et al: High-level IGF1R expression is required for
leukemia-initiating cell activity in T-ALL and is supported by
Notch signaling. J Exp Med. 208:1809–1822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kim EK, Kim JH, Kim HA, Seol H, Seong MK,
Lee JY, Byeon J, Sohn YJ, Koh JS, Park IC and Noh WC:
Phosphorylated S6 kinase-1: A breast cancer marker predicting
resistance to neoadjuvant chemotherapy. Anticancer Res.
33:4073–4079. 2013.PubMed/NCBI
|
|
57
|
Sui P, Cao H, Meng L, Hu P, Ma H and Du J:
The synergistic effect of humanized monoclonal antibodies targeting
insulin-like growth factor 1 receptor (IGF-1R) and chemotherapy.
Curr Drug Targets. 15:674–680. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ge J and Chen Z, Wu S, Chen J, Li X, Li J,
Yin J and Chen Z: Expression levels of insulin-like growth factor-1
and multidrug resistance-associated protein-1 indicate poor
prognosis in patients with gastric cancer. Digestion. 80:148–158.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
de Groot S, Charehbili A, van Laarhoven
HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen
JJ, Smit VT, Heijns JB, et al: Insulin-like growth factor 1
receptor expression and IGF1R 3129G > T polymorphism are
associated with response to neoadjuvant chemotherapy in breast
cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01).
Breast Cancer Res. 18:32016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sun HZ, Wu SF and Tu ZH: Blockage of
IGF-1R signaling sensitizes urinary bladder cancer cells to
mitomycin-mediated cytotoxicity. Cell Res. 11:107–115. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Thomas F, Holly JM, Persad R, Bahl A and
Perks CM: Fibronectin confers survival against chemotherapeutic
agents but not against radiotherapy in DU145 prostate cancer cells:
involvement of the insulin like growth factor-1 receptor. Prostate.
70:856–865. 2010.PubMed/NCBI
|
|
62
|
Eckstein N, Servan K, Hildebrandt B,
Pölitz A, von Jonquières G, Wolf-Kümmeth S, Napierski I, Hamacher
A, Kassack MU, Budczies J, et al: Hyperactivation of the
insulin-like growth factor receptor I signaling pathway is an
essential event for cisplatin resistance of ovarian cancer cells.
Cancer Res. 69:2996–3003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Montazami N, Aghapour M, Farajnia S and
Baradaran B: New insights into the mechanisms of multidrug
resistance in cancers. Cell Mol Biol (Noisy-le-grand). 61:70–80.
2015.PubMed/NCBI
|
|
64
|
Worrall C, Nedelcu D, Serly J, Suleymanova
N, Oprea I, Girnita A and Girnita L: Novel mechanisms of regulation
of IGF-1R action: Functional and therapeutic implications. Pediatr
Endocrinol Rev. 10:473–484. 2013.PubMed/NCBI
|
|
65
|
Chen MY, Clark AJ, Chan DC, Ware JL, Holt
SE, Chidambaram A, Fillmore HL and Broaddus WC: Wilms' tumor 1
silencing decreases the viability and chemoresistance of
glioblastoma cells in vitro: A potential role for IGF-1R
de-repression. J Neurooncol. 103:87–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Qian X, Yu J, Yin Y, He J, Wang L, Li Q,
Zhang LQ, Li CY, Shi ZM, Xu Q, et al: MicroRNA-143 inhibits tumor
growth and angiogenesis and sensitizes chemosensitivity to
oxaliplatin in colorectal cancers. Cell Cycle. 12:1385–1394. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang T, Ge G, Ding Y, Zhou X, Huang Z, Zhu
W, Shu Y and Liu P: MiR-503 regulates cisplatin resistance of human
gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J
(Engl). 127:2357–2362. 2014.PubMed/NCBI
|
|
68
|
Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding
Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of
human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and
BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhuang M, Shi Q, Zhang X, Ding Y, Shan L,
Shan X, Qian J, Zhou X, Huang Z, Zhu W, et al: Involvement of
miR-143 in cisplatin resistance of gastric cancer cells via
targeting IGF1R and BCL2. Tumour Biol. 36:2737–2745. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Verhagen HJ, de Leeuw DC, Roemer MG,
Denkers F, Pouwels W, Rutten A, Celie PH, Ossenkoppele GJ,
Schuurhuis GJ and Smit L: IGFBP7 induces apoptosis of acute myeloid
leukemia cells and synergizes with chemotherapy in suppression of
leukemia cell survival. Cell Death Dis. 5:e13002014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Baxter RC: Insulin-like growth factor
(IGF)-binding proteins: interactions with IGFs and intrinsic
bioactivities. Am J Physiol Endocrinol Metab. 278:E967–E976.
2000.PubMed/NCBI
|
|
72
|
Bach LA: Insulin-like growth factor
binding proteins-an update. Pediatr Endocrinol Rev. 13:521–530.
2015.PubMed/NCBI
|
|
73
|
Beattie J, Allan GJ, Lochrie JD and Flint
DJ: Insulin-like growth factor-binding protein-5 (IGFBP-5): A
critical member of the IGF axis. Biochem J. 395:1–19. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Beech DJ, Perer E, Helms J, Gratzer A and
Deng N: Insulin-like growth factor-I receptor activation blocks
doxorubicin cytotoxicity in sarcoma cells. Oncol Rep. 10:181–184.
2003.PubMed/NCBI
|
|
75
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sun Y, Zheng S, Torossian A, Speirs CK,
Schleicher S, Giacalone NJ, Carbone DP, Zhao Z and Lu B: Role of
insulin-like growth factor-1 signaling pathway in
cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol
Phys. 82:e563–e572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kim TR, Cho EW, Paik SG and Kim IG:
Hypoxia-induced SM22α in A549 cells activates the IGF1R/PI3K/Akt
pathway, conferring cellular resistance against chemo- and
radiation therapy. FEBS Lett. 586:303–309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Werner H and Le Roith D: New concepts in
regulation and function of the insulin-like growth factors:
Implications for understanding normal growth and neoplasia. Cell
Mol Life Sci. 57:932–942. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tracz AF, Szczylik C, Porta C and
Czarnecka AM: Insulin-like growth factor-1 signaling in renal cell
carcinoma. BMC Cancer. 16:4532016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Buck E and Mulvihill M: Small molecule
inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Expert Opin Investig Drugs. 20:605–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ozaki T and Nakagawara A: P53: The
attractive tumor suppressor in the cancer research field. J Biomed
Biotechnol. 2011:6039252011. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Larsson O, Girnita A and Girnita L: Role
of insulin-like growth factor 1 receptor signalling in cancer. Br J
Cancer. 96 Suppl:R2–R6. 2007.PubMed/NCBI
|
|
83
|
Adams JM and Cory S: Bcl-2-regulated
apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol.
19:488–496. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kashyap MK: Role of insulin-like growth
factor-binding proteins in the pathophysiology and tumorigenesis of
gastroesophageal cancers. Tumour Biol. 36:8247–8257. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Jiang ZS, Sun YZ, Wang SM and Ruan JS:
Epithelial-mesenchymal transition: Potential regulator of ABC
transporters in tumor progression. J Cancer. 8:2319–2327. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhang YK, Wang YJ, Gupta P and Chen ZS:
Multidrug resistance proteins (MRPs) and cancer therapy. AAPS J.
17:802–812. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Benabbou N, Mirshahi P, Bordu C, Faussat
AM, Tang R, Therwath A, Soria J, Marie JP and Mirshahi M: A subset
of bone marrow stromal cells regulate ATP-binding cassette gene
expression via insulin-like growth factor-I in a leukemia cell
line. Int J Oncol. 45:1372–1380. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Shen K, Cui D, Sun L, Lu Y, Han M and Liu
J: Inhibition of IGF-IR increases chemosensitivity in human
colorectal cancer cells through MRP-2 promoter suppression. J Cell
Biochem. 113:2086–2097. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Benabbou N, Mirshahi P, Cadillon M, Soria
J, Therwath A and Mirshahi M: Hospicells promote upregulation of
the ATP-binding cassette genes by insulin-like growth factor-I via
the JAK2/STAT3 signaling pathway in an ovarian cancer cell line.
Int J Oncol. 43:685–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Gilkes DM, Semenza GL and Wirtz D: Hypoxia
and the extracellular matrix: Drivers of tumour metastasis. Nat Rev
Cancer. 14:430–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Elliott T and Sethi T: Integrins and
extracellular matrix: A novel mechanism of multidrug resistance.
Expert Rev Anticancer Ther. 2:449–459. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
L Addison C: Modulation of response to
tumor therapies by the extracellular matrix. Future Oncol.
2:417–429. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Sayeed A, Fedele C, Trerotola M, Ganguly
KK and Languino LR: IGF-IR promotes prostate cancer growth by
stabilizing α5β1 integrin protein levels. PLoS One. 8:e765132013.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Prokop I, Konończuk J, Surażyński A and
Pałka J: Cross-talk between integrin receptor and insulin-like
growth factor receptor in regulation of collagen biosynthesis in
cultured fibroblasts. Adv Med Sci. 58:292–297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Packham S, Warsito D, Lin Y, Sadi S,
Karlsson R, Sehat B and Larsson O: Nuclear translocation of IGF-1R
via p150(Glued) and an importin-β/RanBP2-dependent pathway in
cancer cells. Oncogene. 34:2227–2238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Aleksic T, Chitnis MM, Perestenko OV, Gao
S, Thomas PH, Turner GD, Protheroe AS, Howarth M and Macaulay VM:
Type 1 insulin-like growth factor receptor translocates to the
nucleus of human tumor cells. Cancer Res. 70:6412–6419. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sehat B, Tofigh A, Lin Y, Trocmé E,
Liljedahl U, Lagergren J and Larsson O: SUMOylation mediates the
nuclear translocation and signaling of the IGF-1 receptor. Sci
Signal. 3:ra102010. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Sarfstein R, Pasmanik-Chor M, Yeheskel A,
Edry L, Shomron N, Warman N, Wertheimer E, Maor S, Shochat L and
Werner H: Insulin-like growth factor-I receptor (IGF-IR)
translocates to nucleus and autoregulates IGF-IR gene expression in
breast cancer cells. J Biol Chem. 287:2766–2776. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Vesel M, Rapp J, Feller D, Kiss E, Jaromi
L, Meggyes M, Miskei G, Duga B, Smuk G, Laszlo T, et al: ABCB1 and
ABCG2 drug transporters are differentially expressed in non-small
cell lung cancers (NSCLC) and expression is modified by cisplatin
treatment via altered Wnt signaling. Respir Res. 18:522017.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Huang YH, Lin MH, Wang PC, Wu YC, Chiang
HL, Wang YL, Chang JH, Huang YK, Gu SY, Ho HN and Ling TY: Hypoxia
inducible factor 2α/insulin-like growth factor receptor signal loop
supports the proliferation and Oct-4 maintenance of mouse germline
stem cells. Mol Hum Reprod. 20:526–537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Treins C, Giorgetti-Peraldi S, Murdaca J,
Monthouël-Kartmann MN and Van Obberghen E: Regulation of
hypoxia-inducible factor (HIF)-1 activity and expression of HIF
hydroxylases in response to insulin-like growth factor I. Mol
Endocrinol. 19:1304–1317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Popeda M, Pluciennik E and Bednarek AK:
Proteins in cancer multidrug resistance. Postepy Hig Med Dosw
(Online). 68:616–632. 2014.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Genois MM, Paquet ER, Laffitte MC, Maity
R, Rodrigue A, Ouellette M and Masson JY: DNA repair pathways in
trypanosomatids: From DNA repair to drug resistance. Microbiol MoI
Biol Rev. 78:40–73. 2014. View Article : Google Scholar
|
